198 related articles for article (PubMed ID: 37150731)
1. [Tertiary lymphoid structures in cancer: From biology to therapeutic guides].
Quesada S; Lebreton C; Caux C; Italiano A; Dubois B
Bull Cancer; 2023 Jun; 110(6):657-664. PubMed ID: 37150731
[TBL] [Abstract][Full Text] [Related]
2. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract][Full Text] [Related]
4. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
Front Immunol; 2021; 12():690105. PubMed ID: 34054879
[TBL] [Abstract][Full Text] [Related]
5. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
N J; J T; Sl N; Gt B
Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
[TBL] [Abstract][Full Text] [Related]
6. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
7. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
8. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
9. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients.
Yin YX; Ling YH; Wei XL; He CY; Wang BZ; Hu CF; Lin WP; Nie RC; Chen JW; Lin JL; Zhou J; Xie JJ; Yun JP; Xie D; Xue LY; Cai MY
Front Immunol; 2022; 13():973085. PubMed ID: 36591236
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity.
Khanal S; Wieland A; Gunderson AJ
Front Immunol; 2023; 14():1267654. PubMed ID: 37809103
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Associated Tertiary Lymphoid Structures: A Cancer Biomarker and a Target for Next-generation Immunotherapy.
Dieu-Nosjean MC
Adv Exp Med Biol; 2021; 1329():51-68. PubMed ID: 34664233
[TBL] [Abstract][Full Text] [Related]
12. The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer.
Maoz A; Dennis M; Greenson JK
Front Immunol; 2019; 10():1884. PubMed ID: 31507584
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.
Zhang WH; Wang WQ; Han X; Gao HL; Xu SS; Li S; Li TJ; Xu HX; Li H; Ye LY; Lin X; Wu CT; Long J; Yu XJ; Liu L
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33055204
[TBL] [Abstract][Full Text] [Related]
14. Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y; Wu Y; Yan G; Zhang G
Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
[TBL] [Abstract][Full Text] [Related]
15. High endothelial venules proportion in tertiary lymphoid structure is a prognostic marker and correlated with anti-tumor immune microenvironment in colorectal cancer.
Zhan Z; Shi-Jin L; Yi-Ran Z; Zhi-Long L; Xiao-Xu Z; Hui D; Pan YL; Pan JH
Ann Med; 2023 Dec; 55(1):114-126. PubMed ID: 36503344
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC
Front Immunol; 2021; 12():698604. PubMed ID: 34276690
[TBL] [Abstract][Full Text] [Related]
17. Tertiary lymphoid structures in cancer and beyond.
Dieu-Nosjean MC; Goc J; Giraldo NA; Sautès-Fridman C; Fridman WH
Trends Immunol; 2014 Nov; 35(11):571-80. PubMed ID: 25443495
[TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures in cancer - considerations for patient prognosis.
Munoz-Erazo L; Rhodes JL; Marion VC; Kemp RA
Cell Mol Immunol; 2020 Jun; 17(6):570-575. PubMed ID: 32415259
[TBL] [Abstract][Full Text] [Related]
19. High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer.
Vella G; Guelfi S; Bergers G
Front Immunol; 2021; 12():736670. PubMed ID: 34484246
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of tertiary lymphoid structures in cancer.
You X; Koop K; Weigert A
Front Immunol; 2023; 14():1286850. PubMed ID: 38111571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
